Patents Examined by Alicia L Otton
  • Patent number: 11072811
    Abstract: The present invention provides haloalkane substrates, and linkers for connecting such substrates to functional elements (e.g., tags, labels, surfaces, etc.). Substrates and linkers described herein find use, for example, in labeling, detection, and immobilization of proteins, cells, and molecules. In particular, the linkers provided herein find use within substrates for dehalogenase variants that form covalent bonds with their haloalkane substrates.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: July 27, 2021
    Assignee: PROMEGA CORPORATION
    Inventors: Carolyn W. Hitko, Thomas Kirkland, Poncho Meisenheimer, Rachel Friedman Ohana, Harry Tetsuo Uyeda, Ji Zhu
  • Patent number: 11072812
    Abstract: The present invention provides haloalkane substrates, and linkers for connecting such substrates to functional elements (e.g., tags, labels, surfaces, etc.). Substrates and linkers described herein find use, for example, in labeling, detection, and immobilization of proteins, cells, and molecules. In particular, the linkers provided herein find use within substrates for dehalogenase variants that form covalent bonds with their haloalkane substrates.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: July 27, 2021
    Assignee: PROMEGA CORPORATION
    Inventors: Carolyn W. Hitko, Thomas Kirkland, Poncho Meisenheimer, Rachel Friedman Ohana, Harry Tetsuo Uyeda, Ji Zhu
  • Patent number: 11066432
    Abstract: [PROBLEM TO BE SOLVED] It enables any superior ether phospholipids to the conventional ones and a method for producing the same in an easy manner on a massive scale, in light of effects of treating and improving brain diseases such as Alzheimer's disease, Parkinson disease, depression and schizophrenia, metabolic diseases such as diabetes, various infectious diseases, and immune disorders. [SOLUTION] Ether phospholipids are obtained from bivalve tissues such as clams and corbicula by extraction processing. The ether phospholipids exhibit significantly superior effects of the above as compared to the conventional ether phospholipids derived from chicken tissues.
    Type: Grant
    Filed: May 13, 2015
    Date of Patent: July 20, 2021
    Inventors: Takehiko Fujino, Shiro Mawatari
  • Patent number: 11066359
    Abstract: Biodegradable surfactants are described, in which an amphiphilic heteroatom containing hydrocarbon optionally comprising at least one counterion (Z), and related compositions, methods and systems. Biodegradable surfactant described herein has an aHLB value in accordance with equation (1): aHLB=20*Gh/(Gh?Gt) (1) wherein Gh is the Group Number of a hydrophilic head portion of the biodegradable surfactant optionally comprising the at least one counterion (Z), and Gt is the Group Number of a hydrophobic tail portion of the biodegradable surfactant. A biodegradable surfactant in the sense of the disclosure can be tuned to a set hydrophilic-lipophilic balance (aHLB) by selectively modifying at least one tuning moiety of the biodegradable surfactants to provide tuned biodegradable surfactants having an increase or decrease in their adjusted hydrophilic-lipophilic balance (aHLB).
    Type: Grant
    Filed: February 8, 2018
    Date of Patent: July 20, 2021
    Assignee: LAWRENCE LIVERMORE NATIONAL SECURITY, LLC
    Inventors: Mathew Gerald Lyman, Lawrence Dugan, Roald N. Leif, Bonnee Rubinfeld, Brian E. Souza, Carlos A. Valdez
  • Patent number: 11046698
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.
    Type: Grant
    Filed: July 26, 2018
    Date of Patent: June 29, 2021
    Assignee: Nimbus Lakshmi, Inc.
    Inventors: Craig E. Masse, Jeremy Robert Greenwood, Sayan Mondal, Scott D. Cowen, Thomas H. McLean
  • Patent number: 11040941
    Abstract: An alkanethioic acid derivative capable of imparting a characteristic aroma or flavor to fragrances and cosmetics, and foods and beverages; and a perfume composition comprising the alkanethioic acid derivative as an active ingredient. S-alkyl 5-[(1-alkoxy)ethoxy]alkanethioate represented by formula (1), and a perfume composition comprising the S-alkyl 5-[(1-alkoxy)ethoxy]alkanethioate represented by formula (1) as an active ingredient. In the formula (1), R1 represents an alkyl group having 1 to 9 carbon atoms, R2 represents an alkyl group having 2 to 4 carbon atoms, and R3 represents a methyl group or an ethyl group.
    Type: Grant
    Filed: September 12, 2018
    Date of Patent: June 22, 2021
    Assignee: T. HASEGAWA CO., LTD.
    Inventors: Daichi Oguro, Kazuya Kawabata, Akira Nakanishi, Toshifumi Nozawa, Masaki Shimazu
  • Patent number: 11033577
    Abstract: A DDS preparation of a platinum complex, which selectively releases a highly active platinum complex in cells that are under reducing conditions, and exhibits high antitumor activity that is required from a medicine, is still not available, and there is a demand for a novel DDS preparation of a platinum complex that may be used in clinical fields. There is provided a polymer conjugate of a hexa-coordinated platinum complex, the polymer conjugate comprising a block copolymer having a polyethylene glycol structural moiety and a polyaspartic acid moiety or a polyglutamic acid moiety; and a hexa-coordinated platinum complex having a halogen atom and a hydroxyl group at the axial positions, the hexa-coordinated platinum complex being bonded, directly or via a spacer, to a side-chain carboxyl group of the block copolymer.
    Type: Grant
    Filed: June 5, 2019
    Date of Patent: June 15, 2021
    Assignee: Nippon Kayaku Kabushiki Kaisha
    Inventors: Masaharu Nakamura, Tsuyoshi Fukuda, Yusaku Kikuchi, Chihiro Watanabe
  • Patent number: 11020411
    Abstract: Disclosed herein are compounds comprising dicarba-closo-dodecaborane. The compounds can be, for example, estrogen receptor beta (ER?) agonists. In some examples, the compounds can be selective ER? agonists. Also provided herein are methods of treating, preventing, or ameliorating cancer in a subject, suppressing tumor growth in a subject, treating an inflammatory disease in a subject, treating a neurodegenerative disease in a subject, treating a psychotropic disorder in a subject, or a combination thereof by administering to a subject a therapeutically effective amount of one or more of the compounds or compositions described herein, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 19, 2016
    Date of Patent: June 1, 2021
    Assignees: OHIO STATE INNOVATION FOUNDATION, INSTITUTE OF MOLECULAR GENETICS AS CR, V.V.I.
    Inventors: Werner Tjarks, Petr Bartunek, David Sedlak
  • Patent number: 11020374
    Abstract: Sulcardine salts other than sulfuric acid salts of sulcardine, including crystalline sulcardine salts, are provided herein. Pharmaceutical compositions comprising such salts and methods of treating arrhythmias comprising administering effective amounts of such salts are also provided.
    Type: Grant
    Filed: October 23, 2020
    Date of Patent: June 1, 2021
    Assignee: HUYA Bioscience International, LLC
    Inventors: Suzanne J. Romano, Hayley Ann Reece, Joseph Edward Gordon Benson, Sarah Collins, Gary T. Elliott, Mireille Gillings, Robert Goodenow, Curtis Tyree
  • Patent number: 11022556
    Abstract: The object of the present invention is to provide a compound used in a reagent for detecting microorganisms, by which microorganisms can be rapidly and reliably detected without requiring any special instrument, the reagent for detecting microorganisms, and a method for detecting microorganisms. The object can be achieved by a tetrazolium compound represented by general formula (I) below: wherein the symbols are as defined in the description, a chromogenic reagent for detecting microorganism comprising the tetrazolium compound, or a method for detecting microorganisms using the chromogenic reagent.
    Type: Grant
    Filed: March 16, 2011
    Date of Patent: June 1, 2021
    Assignee: JNC CORPORATION
    Inventors: Yuichi Onji, Masashi Ushiyama
  • Patent number: 11014876
    Abstract: Cancer is a disease for which there remains a great unmet medical need, and therefore the discovery and development of new antineoplastic agents is critically important. The present invention relates in part to new therapeutic compounds with antineoplastic activity. Provided herein are polyamine sulfonamides such as compounds of Formula (I), or pharmaceutically acceptable salts thereof, which may be used in the treatment and/or prevention of diseases such as cancer. Also provided herein are pharmaceutical compositions and kits comprising the inventive compounds. Furthermore, the present invention provides methods of treating and/or preventing diseases (e.g., cancer) using compounds of Formula (I), or pharmaceutically acceptable salts thereof or pharmaceutical compositions thereof. Other methods provided include methods for inducing apoptosis of a cell, as well as methods for inhibiting alpha-enolase enzymatic activity in vivo and in vitro.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: May 25, 2021
    Assignees: University of Florida Research Foundation, Inc., Torrey Pines Institute for Molecular Studies
    Inventors: Christopher R. Cogle, Amy M. Meacham, Peter P. Sayeski, Marcello A. Giulianotti, Richard A. Houghten, Gregory S. Welmaker
  • Patent number: 11008313
    Abstract: The present invention relates to PCSK9 allosteric binding compounds of Formula I: (Formula (I)) and pharmaceutically acceptable salts thereof, wherein X1, X2, Y, R1, R2, RA, RB and n are as defined herein. The present invention also relates to compositions which comprise an allosteric binding compound of the invention or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. The invention further relates, inter alia, to methods for inducing PCSK9 protein degradation in a subject, and methods for treating atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome, or related cardiovascular disease and cardiometabolic conditions, comprising administering to a subject an effective amount of a compound or a pharmaceutically acceptable salt of the invention. The invention also provides a means for the in vitro labeling, detection and/or quantification of PCSK9 in biological samples.
    Type: Grant
    Filed: September 15, 2017
    Date of Patent: May 18, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jason Eugene Imbriglio, Whitney Lane Petrilli, Yusheng Xiong, Zhe Feng, Hyewon Youm, Wonsuk Chang, Rui Liang, Zhijian Lu, Jerry Andrew Taylor, Scott B. Hoyt
  • Patent number: 11008340
    Abstract: Provided are novel compounds of Formula I: pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by ROR?. Also provided are pharmaceutical compositions comprising the novel compounds of Formula I and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: May 18, 2021
    Assignee: Vitae Pharmaceuticals, LLC
    Inventors: David A. Claremon, Lawrence Wayne Dillard, Yi Fan, Lanqi Jia, Suresh B. Singh, Colin M. Tice, Zhenrong Xu, Jing Yuan, Linghang Zhuang
  • Patent number: 11008300
    Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.
    Type: Grant
    Filed: January 16, 2020
    Date of Patent: May 18, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Yan Shi, Peter Tai Wah Cheng, Ying Wang, Jun Shi, Shiwei Tao, Jun Li, Lawrence J. Kennedy, Robert F. Kaltenbach, III, Hao Zhang, James R. Corte
  • Patent number: 11001555
    Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, A, X and R11 are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: February 22, 2019
    Date of Patent: May 11, 2021
    Assignee: Hoffman-La Roche Inc.
    Inventors: Benoit Hornsperger, Hans P. Maerki, Peter Mohr, Michael Reutlinger, Markus Rudolph
  • Patent number: 10988684
    Abstract: To provide an electrochromic compound represented by the following general formula (1) where X1 and X2 are each independently a carbon atom or a nitrogen atom, R1, R2 and R3 are each independently a halogen atom, a substituted or unsubstituted alkyl group, or a substituted or unsubstituted alkoxy group, x is an integer selected from 0 through 3, y and z are each independently an integer selected from 0 through 4, and at least one of L1 and L2 is a monovalent functional group bonded to a nitrogen atom of a pyridinium ring directly, or via a divalent substituent.
    Type: Grant
    Filed: February 9, 2016
    Date of Patent: April 27, 2021
    Assignee: RICOH COMPANY, LTD.
    Inventors: Toshiya Sagisaka, Satoshi Yamamoto, Takashi Okada, Masato Shinoda, Shigenobu Hirano, Fuminari Kaneko, Mamiko Inoue, Daisuke Goto, Tohru Yashiro
  • Patent number: 10986839
    Abstract: The present invention relates to novel trifluoromethyloxadiazoles of the formula I, or an N-oxide and/or their agriculturally useful salts and to their use for controlling phytopathogenic fungi; to a method for combating phytopathogenic harmful fungi, which process comprises treating the fungi or the plants, the soil or seeds to be protected against fungal attack, with an effective amount of at least one compound of the formula I, or an N-oxide, or an agriculturally acceptable salt thereof; to a process for preparing compounds of the formula I; to intermediate compounds of the formula II.a for the preparation of compounds of the formula I; to agrochemical compositions comprising at least one compound of the formula I; and to agrochemical compositions further comprising seeds.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: April 27, 2021
    Assignee: BASF SE
    Inventors: Violeta Terteryan-Seiser, Wassilios Grammenos, Christine Wiebe, Manuel Kretschmer, Ian Robert Craig, Ana Escribano Cuesta, Marcus Fehr, Tobias Mentzel, Maria Angelica Quintero Palomar, Thomas Grote, Erica Cambeis, Bernd Mueller, Jan Klaas Lohmann, Christian Harald Winter
  • Patent number: 10981868
    Abstract: A one-pot process for the manufacture of 5-chloro-7-methylindoline-2,3-dione starting from 2-hydroxyimino-N-(2-methylphenyl)acetamide via tandem cyclization in sulfuric acid and acetic acid, followed by in-situ chlorination with sulfur dioxide and chlorine gas in high regioselectivity and yield.
    Type: Grant
    Filed: August 12, 2020
    Date of Patent: April 20, 2021
    Assignee: Tagros Chemicals India Pvt. Ltd.
    Inventor: Bomi P Framroze
  • Patent number: 10975049
    Abstract: The present invention discloses a nicotinyl alcohol ether derivative, a preparation method therefor, and a pharmaceutical composition and uses thereof. Specifically, the invention relates to nicotinyl alcohol ether derivatives represented by formula (I), a pharmaceutically-acceptable salt thereof, a stereoisomer thereof, a preparation method therefor, a pharmaceutical composition containing the one or more compounds, and uses of the compounds in treating diseases related to PD-1/PD-L1 signal channels, such as cancers, infectious diseases and autoimmune diseases.
    Type: Grant
    Filed: May 23, 2017
    Date of Patent: April 13, 2021
    Assignees: Institute of Materia Medica, Chinese Academy of Medical Sciences, Tianjin Chase Sun Pharmaceutical Co., LTD
    Inventors: Zhiqiang Feng, Xiaoguang Chen, Yang Yang, Yi Zheng, Fangfang Lai, Ming Ji, Chuan Zhou, Lijing Zhang, Ke Wang, Nina Xue, Ling Li
  • Patent number: 10973828
    Abstract: The application relates to biaryl compounds, pharmaceutical compositions comprising the compounds, and methods of use the compounds for treating cell proliferation disorders.
    Type: Grant
    Filed: December 26, 2018
    Date of Patent: April 13, 2021
    Assignee: Athenex, Inc.
    Inventors: Michael P. Smolinski, Nader N. Nasief Abdel-Sayed, David G. Hangauer, Jr.